Sign in
Download Opera News App

Stock-investment

Pfizer's All-in Costs Show Vaccine Probably Won't Move the Needle Much

Pfizer's All-in Costs Show Vaccine Probably Won't Move the Needle Much

For all the hoopla, PFE stock has already seen the benefit of the Covid-19 vaccine and needs new catalysts Due to a combination of several factors, Pfizer’s (NYSE:PFE) vaccine for the novel coronavirus, by itself, may not ever move the needle a great deal for PFE stock. Source: Manuel Esteban / Shutterstock.com On the other hand, over the long-term, Pfizer’s collaboration with...

Read Full Story
BioNTech Covid-19 German Manuel Esteban NYSE Pfizer